Cited by 294Acute Myeloid Leukemia ResearchEpigenetics and DNA MethylationRetinoids in leukemia and cellular processes

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Open access

Fiskus, W, Sharma, S, Shah, B, Portier, B P, Devaraj, S G T, Liu, K, Iyer, S P, Bearss, D, Bhalla, K N·2014·Leukemia

DOI 10.1038/leu.2014.119PMC PMC4739780

Open this paper in CoChat — free account

Abstract

The histone demethylase LSD1 (KDM1A) demethylates mono- and di-methylated (Me2) lysine (K) 4 on histone H3. High LSD1 expression blocks differentiation and confers a poor prognosis in acute myeloid leukemia (AML). Here, treatment with the novel LSD1 antagonist SP2509 attenuated the binding of LSD1 with the corepressor CoREST, increased the permissive H3K4Me3 mark on the target gene promoters, and increased the levels of p21, p27 and CCAAT/enhancer binding protein α in cultured AML cells. In addition, SP2509 treatment or LSD1 shRNA inhibited the colony growth of AML cells. SP2509 also induced morphological features of differentiation in the cultured and primary AML blasts. SP2509 induced more apoptosis of AML cells expressing mutant NPM1 than mixed-lineage leukemia fusion oncoproteins. Treatment with SP2509 alone significantly improved the survival of immune-depleted mice following tail-vein infusion and engraftment of cultured or primary human AML cells. Co-treatment with pan-HDAC inhibitor (HDI) panobinostat (PS) and SP2509 was synergistically lethal against cultured and primary AML blasts. Compared with each agent alone, co-treatment with SP2509 and PS significantly improved the survival of the mice engrafted with the human AML cells, without exhibiting any toxicity. Collectively, these findings show that the combination of LSD1 antagonist and pan-HDI is a promising therapy warranting further testing against AML.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/leu.2014.119

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
The origin and evolution of mutations in acute myeloid leukemia
Welch, J. S., Ley, T. J., Link, D. C., Miller, C. A., Larson, D. E., Koboldt, D. C., Wartman, L. D., Lamprecht, T. L., Liu, F., Xia, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.023 · Cited by 1,575
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Interplay between the Cancer Genome and Epigenome
Shen, H., & Laird, P. W. (2013) · Cell · doi:10.1016/j.cell.2013.03.008 · Cited by 949
Molecular mechanisms and potential functions of histone demethylases
Kooistra, S. M., & Helin, K. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3327 · Cited by 913
Regulation of LSD1 Histone Demethylase Activity by Its Associated Factors
Shi, Y.-J., Matson, C., Lan, F., Iwase, S., Baba, T., & Shi, Y. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.027 · Cited by 906
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation
Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2008) · Nature Genetics · doi:10.1038/ng.268 · Cited by 827
p53 is regulated by the lysine demethylase LSD1
Huang, J. L., Sengupta, R., Espejo, A. B., Lee, M. G., Dorsey, J. A., Richter, M., Opravil, S., Shiekhattar, R., Bedford, M. T., Jenuwein, T., et al. (2007) · Nature · doi:10.1038/nature06092 · Cited by 820
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2661 · Cited by 672
Enhancer decommissioning by LSD1 during embryonic stem cell differentiation
Whyte, W. A., Bilodeau, S., Orlando, D. A., Hoke, H. A., Frampton, G. M., Foster, C. T., Cowley, S. M., & Young, R. A. (2012) · Nature · doi:10.1038/nature10805 · Cited by 602

Flagged first, then by citations

Show all 45 references

Sorted by citations

Epigenetic Determinants of CancerPreprint
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,414
HDACs and HDAC Inhibitors in Cancer Development and TherapyPreprint
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,337
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
LSD1/KDM1A inhibitors in clinical trials: advances and prospects
Fang, Y., Liao, G., & Yu, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0811-9 · Cited by 453
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy
Morera, L., Lübbert, M., & Jung, M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0223-4 · Cited by 412
Critical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Bose, P., Vachhani, P. J., & Cortes, J. E. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0456-2 · Cited by 241
LSD1 activates a lethal prostate cancer gene network independently of its demethylase function
Sehrawat, A., Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J. A., Urrutia, J. A., Bisson, W. H., Coleman, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719168115 · Cited by 226
Self-citation
HDAC Inhibitors in Acute Myeloid Leukemia
José‐Eneriz, E. S., Gimenez-Camino, N., Agirre, X., & Prósper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 224
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia
Maiqués-Díaz, A., Spencer, G. J., Lynch, J. T., Ciceri, F., Williams, E. L., Amaral, F. M. R., Wiseman, D. H., Harris, W. J., Li, Y., Sahoo, S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.012 · Cited by 208
LSD1: Biologic Roles and Therapeutic Targeting
Maiqués-Díaz, A., & Somervaille, T. C. P. (2016) · Epigenomics · doi:10.2217/epi-2016-0009 · Cited by 207
A Systematic Review of Histone Lysine‐Specific Demethylase 1 and Its Inhibitors
Zheng, Y., Ma, J., Wang, Z., Li, J., Jiang, B., Zhou, W., Shi, X., Wang, X., Zhao, W., & Liu, H. (2015) · Medicinal Research Reviews · doi:10.1002/med.21350 · Cited by 196
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
Anastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M. A., Giera, S., Gillespie, S. M., Das, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.005 · Cited by 197
Targeting histone lysine methylation in cancer
McGrath, J. P., & Trojer, P. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.002 · Cited by 190
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Poole, C. J., & van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 180
Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends
Nepali, K., & Liou, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00721-x · Cited by 187
Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
Song, Y., Wu, F., & Wu, J. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0279-9 · Cited by 154
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs
Brien, G. L., Valerio, D. G., & Armstrong, S. A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.007 · Cited by 155
Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date
Mould, D. P., McGonagle, A. E., Wiseman, D. H., Williams, E. L., & Jordan, A. M. (2014) · Medicinal Research Reviews · doi:10.1002/med.21334 · Cited by 138
A Comprehensive Review of Lysine-Specific Demethylase 1 and its Roles in Cancer
Hosseini, A., & Minucci, S. (2017) · Epigenomics · doi:10.2217/epi-2017-0022 · Cited by 139
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma
Huang, M., Chen, C. Y., Geng, J., Han, D. H., Wang, T., Xie, T., Wang, L., Wang, Y., Wang, C., Lei, Z., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.038 · Cited by 134
Advances Toward Lsd1 Inhibitors for Cancer Therapy
Fu, X., Zhang, P., & Yu, B. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0068 · Cited by 133
Pharmacological Inhibition of LSD1 for Cancer Treatment
Yang, G., Lei, P.-M., Wong, S.-Y., Ma, D., & Leung, C. (2018) · Molecules · doi:10.3390/molecules23123194 · Cited by 129
Histone Demethylases and Their Roles in Cancer Epigenetics
D’Oto, A., Tian, Q., Davidoff, A. M., & Yang, J. (2016) · Journal of medical oncology and therapeutics · doi:10.35841/medical-oncology.1.2.34-40 · Cited by 127
Natural products as LSD1 inhibitors for cancer therapy
Fang, Y., Yang, C., Yu, Z., Li, X., Mu, Q., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.06.007 · Cited by 125
Biological roles of LSD1 beyond its demethylase activity
Gu, F., Lin, Y., Wang, Z., Wu, X., Ye, Z., Wang, Y., & Lan, H. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03489-9 · Cited by 121
Advances in the development of histone lysine demethylase inhibitors
Maes, T., Carceller, E., Salas‐Salvadó, J., Ortega, A., & Buesa, C. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.009 · Cited by 123
The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia
Baker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 117
LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML
Cusan, M., Cai, S. F., Mohammad, H. P., Krivtsov, A. V., Chramiec, A. G., Loizou, E., Witkin, M. D., Smitheman, K. N., Tenen, D. G., Ye, M., et al. (2018) · Blood · doi:10.1182/blood-2017-09-807024 · Cited by 120
A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells
Ishikawa, Y., Gamo, K., Yabuki, M., Takagi, S., Toyoshima, K., Nakayama, K., Nakayama, A., Morimoto, M., Miyashita, H., Dairiki, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0471 · Cited by 113
Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes
McGrath, J. P., Williamson, K. E., Balasubramanian, S., Odate, S., Arora, S., Hatton, C., Edwards, T. M., O’Brien, T., Magnuson, S. R., Stokoe, D., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2333 · Cited by 107
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia
Li, Y., Zhang, M., Sheng, M., Zhang, P., Chen, Z., Xing, W., Bai, J., Cheng, T., Yang, F., & Zhou, Y. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2631-7 · Cited by 112
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Wass, M., Göllner, S., Besenbeck, B., Schlenk, R. F., Mundmann, P., Göthert, J. R., Noppeney, R., Schliemann, C., Mikesch, J., Lenz, G., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0892-z · Cited by 106
Targeting the canonical Wnt/β‐catenin pathway in hematological malignancies
Ashihara, E., Takada, T., & Maekawa, T. (2015) · Cancer Science · doi:10.1111/cas.12655 · Cited by 109
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Feng, Z., Yao, Y., Zhou, C., Chen, F., Wu, F., Wei, L., Liu, W., Dong, S., Redell, M. S., Mo, Q., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0252-7 · Cited by 107
LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression
Liang, Y., Ahmed, M., Guo, H., Soares, F., Hua, J. T., Gao, S., Lu, C., Poon, C., Han, W., Langstein, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0496 · Cited by 100
Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway
Sareddy, G. R., Viswanadhapalli, S., Surapaneni, P., Suzuki, T., Brenner, A. J., & Vadlamudi, R. (2016) · Oncogene · doi:10.1038/onc.2016.395 · Cited by 99
Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W. C., Sharma, S., Saha, S., Shah, B. N., Devaraj, S. G. T., Sun, B., Horrigan, S. K., Leveque, C. M., Zu, Y., Iyer, S. P., et al. (2014) · Leukemia · doi:10.1038/leu.2014.340 · Cited by 102
Self-citation
Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells
Wu, D., Wang, W., Chen, W., Lian, F., Lang, L., Huang, Y., Xu, Y., Zhang, N., Chen, Y., Liu, M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.188185 · Cited by 97
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment
Duan, Y., Ma, Y., Qin, W., Ding, L., Zheng, Y., Zhu, Y., Zhai, X.-Y., Yang, J. C., Ma, C.-Y., & Guan, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.038 · Cited by 95
Lysine-specific demethylase LSD1 regulates autophagy in neuroblastoma through SESN2-dependent pathway
Ambrosio, S., Saccà, C. D., Amente, S., Paladino, S., Lania, L., & Majello, B. (2017) · Oncogene · doi:10.1038/onc.2017.267 · Cited by 92
Lysine-Specific Demethylase 1A as a Promising Target in Acute Myeloid Leukemia
Magliulo, D., Bernardi, R., & Messina, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00255 · Cited by 90
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Epigenetic Deregulation of Apoptosis in Cancers
Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 94
KDM1 Histone Lysine Demethylases as Targets for Treatments of Oncological and Neurodegenerative Disease
Maes, T., Mascaró, C., Ortega, A., Lunardi, S., Ciceri, F., Somervaille, T. C. P., & Buesa, C. (2015) · Epigenomics · doi:10.2217/epi.15.9 · Cited by 88
Targeting LSD1 for acute myeloid leukemia (AML) treatment
Zhang, S., Liu, M., Yao, Y., Yu, B., & Liu, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105335 · Cited by 85
Digging deep into “dirty” drugs – modulation of the methylation machinery
Pleyer, L., & Greil, R. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.995379 · Cited by 84
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer
Lin, K., Rutter, J. C., Xie, A., Pardieu, B., Winn, E. T., Bello, R. D., Forget, A., Itzykson, R., Ahn, Y.-R., Dai, Z., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0590-9 · Cited by 88
TCPs: Privileged Scaffolds for Identifying Potent LSD1 Inhibitors for Cancer Therapy
Zheng, Y., Yu, B., Chen, Z., Liu, Y., & Liu, H. (2016) · Epigenomics · doi:10.2217/epi-2015-0002 · Cited by 84
Development of the triazole-fused pyrimidine derivatives as highly potent and reversible inhibitors of histone lysine specific demethylase 1 (LSD1/KDM1A)
Li, Z., Ding, L., Li, Z., Wang, Z., Suo, F., Shen, D., Zhao, T., Sun, X., Wang, J., Liu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.01.001 · Cited by 83
Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma
Singh, M. M., Johnson, B., Venkatarayan, A., Flores, E. R., Zhang, J., Su, X., Barton, M. C., Lang, F., & Chandra, J. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov041 · Cited by 83
KRT6A Promotes Lung Cancer Cell Growth and Invasion Through MYC-Regulated Pentose Phosphate Pathway
Che, D., Wang, M., Sun, J., Li, B., Xu, T., Lu, Y., Pan, H., Lu, Z., & Gu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.694071 · Cited by 82
Efficient combinatorial targeting of RNA transcripts in single cells with Cas13 RNA Perturb-seq
Wessels, H.-H., Méndez-Mancilla, A., Hao, Y., Papalexi, E., Mauck, W. M., Lu, L., Morris, J. A., Mimitou, E. P., Smibert, P., Sanjana, N. E., et al. (2023) · Nature Methods · doi:10.1038/s41592-022-01705-x · Cited by 79
KDM1A microenvironment, its oncogenic potential, and therapeutic significance
Ismail, T., Lee, H.-K., Kim, C., Kwon, T., Park, T. J., & Lee, H. (2018) · Epigenetics & Chromatin · doi:10.1186/s13072-018-0203-3 · Cited by 77
Epigenetic regulation of endothelial‐cell‐mediated vascular repair
Fraineau, S., Palii, C. G., Allan, D., & Brand, M. (2014) · FEBS Journal · doi:10.1111/febs.13183 · Cited by 80
Histone Lysine Demethylase InhibitorsPreprint
Jambhekar, A., Anastas, J. N., & Shi, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026484 · Cited by 76
Emerging approaches for histone deacetylase inhibitor drug discovery
Zwergel, C., Valente, S., Jacob, C., & Mai, A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1038236 · Cited by 77
A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers
Sugino, N., Kawahara, M., Tatsumi, G., Kanai, A., Matsui, H., Yamamoto, R., Nagai, Y., Fujii, S., Shimazu, Y., Hishizawa, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.59 · Cited by 76
LSD1 inhibition by tranylcypromine derivatives interferes with GFI1-mediated repression of PU.1 target genes and induces differentiation in AML
Barth, J., Abou‐El‐Ardat, K., Dalic, D., Kurrle, N., Maier, A., Mohr, S., Schütte, J., Vaßen, L., Greve, G., Schulz‐Fincke, J., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0375-7 · Cited by 75
Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells
Zhang, Z., Lei, A., Xu, L., Chen, L., Chen, Y., Zhang, X., Gao, Y., Yang, X., Zhang, M., & Cao, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.785865 · Cited by 73
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.54 · Cited by 71
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting
Theisen, E. R., Pishas, K. I., Saund, R. S., & Lessnick, S. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7124 · Cited by 70
Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia
Lambert, M., Alioui, M., Jambon, S., Depauw, S., SEUNINGEN, I. V., & David‐Cordonnier, M. (2019) · Cancers · doi:10.3390/cancers11060837 · Cited by 73
Role of Lysine‐Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia‐Inducible Factor 1α and E2F1
Doi, K., Murata, K., Ito, S., Suzuki, A., Terao, C. C., Ishie, S., Umemoto, A., Murotani, Y., Nishitani, K., Yoshitomi, H., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42074 · Cited by 70
KDM1 class flavin‐dependent protein lysine demethylases
Burg, J. M., Link, J. E., Morgan, B. S., Heller, F. J., Hargrove, A. E., & McCafferty, D. G. (2015) · Biopolymers · doi:10.1002/bip.22643 · Cited by 72
Codelivery of doxorubicin and triptolide with reduction-sensitive lipid–polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment
Wu, B., Lu, S., Zhang, L.-J., Zhuo, R., Xu, H., & Huang, S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131235 · Cited by 69
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome
Raynal, N. J. ‐., Costa, E. M. D., Lee, J. T., Gharibyan, V., Ahmed, S., Zhang, H., Sato, T., Malouf, G. G., & Issa, J. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0588 · Cited by 67
Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1
Lü, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0637 · Cited by 68
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009829 · Cited by 68
Pharmacoepigenetics and Toxicoepigenetics: Novel Mechanistic Insights and Therapeutic Opportunities
Lauschke, V. M., Barragán, I., & Ingelman‐Sundberg, M. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053021 · Cited by 63
Histone methylation in DNA repair and clinical practice: new findings during the past 5-years
Wei, S., Li, C., Yin, Z., Wen, J., Meng, H., Xue, L., & Wang, J. (2018) · Journal of Cancer · doi:10.7150/jca.23427 · Cited by 67
Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation
Duan, Y., Guan, Y., Zhai, X.-Y., Ding, L., Qin, W., Shen, D., Liu, X., Sun, X., Zheng, Y., & Liu, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.11.035 · Cited by 61
Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia
Togasaki, E., Takeda, J., Yoshida, K., Shiozawa, Y., Takeuchi, M., Oshima, M., Saraya, A., Iwama, A., Yokote, K., Sakaida, E., et al. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.36 · Cited by 61
Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia
Sun, Y., Chen, B.-R., & Deshpande, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 64
Current Advances in Coptidis Rhizoma for Gastrointestinal and Other Cancers
He, L., Zhong, Z., Chen, M., Liang, Q., Wang, Y., & Tan, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.775084 · Cited by 57
Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases
Niwa, H., & Umehara, T. (2017) · Epigenetics · doi:10.1080/15592294.2017.1290032 · Cited by 57
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
Haydn, T., Metzger, E., Schüle, R., & Fulda, S. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.239 · Cited by 59
LSD1 inhibition suppresses the growth of clear cell renal cell carcinoma via upregulating P21 signaling
Zhu, L., Wang, J., Kong, W., Huang, J., Dong, B., Huang, Y., Xue, W., & Zhang, J. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.10.006 · Cited by 59
Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer
Duan, Y., Jin, L., Ren, H.-M., Zhang, S., Liu, Y.-J., Xu, Y., He, Z., Song, Y., Yuan, H., Chen, S.-H., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113453 · Cited by 55
Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Tayari, M. M., Santos, H. G. D., Kwon, D., Bradley, T., Thomassen, A., Chen, C. Y., Dinh, Y. T., Perez, A., Zelent, A., Morey, L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4054 · Cited by 53
SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells
Piao, L., Suzuki, T., Dohmae, N., Nakamura, Y., & Hamamoto, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4760 · Cited by 58
Stepwise assembly of functional C‐terminal REST/NRSF transcriptional repressor complexes as a drug target
Inui, K., Zhao, Z., Yuan, J., Jayaprakash, S., Le, L. T. M., Drakulić, S., Sander, B. O., & Golas, M. M. (2017) · Protein Science · doi:10.1002/pro.3142 · Cited by 54
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Stahl, M. F., Gore, S. D., Vey, N., & Prébet, T. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1146251 · Cited by 52
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
Wang, Z., Townley, S. L., Zhang, S., Liu, M., Li, M., Labaf, M., Patalano, S. C., Venkataramani, K., Siegfried, K. R., Macoska, J. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49234-9 · Cited by 51
Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A
Ambrosio, S., Saccà, C. D., & Majello, B. (2017) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2017.07.001 · Cited by 52
Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignancies
Chao, A., Lin, C., Chao, A., Tsai, C.-L., Chen, M., Lee, L., Chang, T., Wang, T., Lai, C., & Wang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20158 · Cited by 51
Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
Castelli, G., Pelosi, E., & Testa, U. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145971 · Cited by 51
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 50
Medicinal Chemistry Insights in the Discovery of Novel LSD1 Inhibitors
Wang, X., Huang, B., Suzuki, T., Liu, X., & Zhan, P. (2015) · Epigenomics · doi:10.2217/epi.15.86 · Cited by 50
LSD1 inhibitors: a patent review (2010-2015)
Stazi, G., Zwergel, C., Valente, S., & Mai, A. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1165209 · Cited by 51
Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation
Li, Z., Suo, F., Guo, Y.-J., Cheng, H.-F., Niu, S.-H., Shen, D., Zhao, L., Liu, Z., Maa, M., Yu, B., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103648 · Cited by 49
Epigenetics: A primer for clinicians
Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 50
Reversible lysine-specific demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-MYC in castration- and docetaxel-resistant prostate cancer cells
Gupta, S. V., Weston, A., Bearss, J. J., Thode, T. G., Neiss, A., Soldi, R., & Sharma, S. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.21 · Cited by 50
Self-citation
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Epigenetic regulators and their impact on therapy in acute myeloid leukemia
Pastore, F., & Levine, R. L. (2016) · Haematologica · doi:10.3324/haematol.2015.140822 · Cited by 49
MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response
Qiu, H., Jin, B., Wang, Z., Xu, B., Zheng, Q., Zhang, L., Zhu, L.-Y., Shi, S., Yuan, J.-B., Lin, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14614-4 · Cited by 49
Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice
O’Connor, O. A., Bhagat, G., Ganapathi, K. A., Pedersen, M. B., d’Amore, F., Radeski, D., & Bates, S. E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2020 · Cited by 47
Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo
Wen, S., Wang, J., Liu, P., Li, Y., Lu, W., Hu, Y., Liu, J., He, Z., & Huang, P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.015 · Cited by 47
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines
Welch, D. L., Kahen, E., Fridley, B. L., Brohl, A. S., Cubitt, C. L., & Reed, D. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222228 · Cited by 46

Authors: Fiskus, W., Sharma, S., Shah, B., Portier, B. P., Devaraj, S. G. T., Liu, K., Iyer, S. P., Bearss, D., & Bhalla, K. N.
Affiliations: Houston Methodist (US)
University of Utah (US)
Brigham Young University (US)
Corresponding author: Bhalla, K N
ORCID: Fiskus, W
Sharma, S
Shah, B
Portier, B P
Iyer, S P
Bearss, D
Bhalla, K N
Venue: Leukemia
Publisher: Springer Science and Business Media LLC
Published: 2014-04-04
Volume: 28
Issue: 11
Pages: 2155-2164
ISSN: 0887-6924 (ISSN-L)
1476-5551
DOI: 10.1038/leu.2014.119
PMC: PMC4739780
OpenAlex: W2006229882
Cited by: 284
References: 45
Citations by year: 2026: 8 · 2025: 14 · 2024: 21 · 2023: 18 · 2022: 20 · 2021: 18 · 2020: 25 · 2019: 27 · 2018: 26 · 2017: 45 · 2016: 35 · 2015: 21 · 2014: 5
FWCI: 25.06
Type: journal article
Language: en
Update notices: erratum (2017-03-21)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Leukemia (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA171338, R01CA173877, R01CA123207)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords: LSD1, acute myeloid leukemia, histone deacetylase inhibitors, panobinostat, combination therapy, H3K4 demethylation, leukemia cell differentiation, apoptosis, NPM1 mutation, MLL fusion, synergistic lethality
MeSH terms: Nucleophosmin, Animals, Cells, Cultured, Disease Models, Animal, Enzyme Inhibitors, Female, Histones, Humans, Hydrazines, Nerve Tissue Proteins, Stem Cells, Sulfonamides, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Mice, SCID, Mice, Inbred NOD, Apoptosis, Xenograft Model Antitumor Assays, RNA, Small Interfering, Histone Acetyltransferases, Histone Demethylases, Co-Repressor Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks